First reported at 12,175,159 shares this quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2026-09-30 | 245938212 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | New | 12,175,159 | +12,175,159 (0.0%) | 4.49% | $245,938,212 | 2026-11-16 |
Who else reported the position
64 managers reported BRAVEHEART BIO INC COM for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FCPM III SERVICES B V | New | 21,826,024 | +21,826,024 | 41.57% | $440,885,685 | 1 qtr |
| ORBIMED ADVISORS LLC This report | New | 12,175,159 | +12,175,159 | 4.49% | $245,938,212 | 1 qtr |
| AH Capital Management L L C | New | 10,232,420 | +10,232,420 | 1.04% | $206,694,884 | 1 qtr |
| FMR LLC | New | 7,585,769 | +7,585,769 | < 0.01% | $153,232,533 | 1 qtr |
| Frazier Life Sciences Management L P | New | 5,267,321 | +5,267,321 | 2.64% | $106,399,884 | 1 qtr |
| Enavate Sciences GP LLC | New | 3,674,656 | +3,674,656 | 26.53% | $74,228,051 | 1 qtr |
| Capital International Investors | New | 1,300,000 | +1,300,000 | < 0.01% | $26,260,000 | 1 qtr |
| Avoro Capital Advisors LLC | New | 1,255,000 | +1,255,000 | 0.26% | $25,351,000 | 1 qtr |
| Capital Research Global Investors | New | 1,034,097 | +1,034,097 | < 0.01% | $20,888,759 | 1 qtr |
| BlackRock Inc | New | 1,007,129 | +1,007,129 | < 0.01% | $20,344,007 | 1 qtr |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 16, 2026
- Filing type
- 13F-HR
- Position type
- COM SHS
Voting authority reported
- Sole
- 12,175,159
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.